Skip to main content

Navigation group

Type at least 3 characters
16,741 articles

Articles

Study Protocol

Published on 13 Aug 2024

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)

in Multiple Sclerosis and Neuroimmunology

  • Soon-Tae Lee
  • Hesham Abboud
  • Sarosh R. Irani
  • Hideto Nakajima
  • Amanda L. Piquet
  • Sean J. Pittock
  • E. Ann Yeh
  • Jiawei Wang
  • Sharmila Rajan
  • James Overell
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
Frontiers in Neurology
doi 10.3389/fneur.2024.1437913
  • 2,675 views